Evommune, Inc. (NYSE:EVMN - Get Free Report) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $7.19 and traded as high as $7.39. Evommune shares last traded at $7.2220, with a volume of 474,788 shares traded.
Analyst Ratings Changes
Several analysts have issued reports on EVMN shares. Weiss Ratings downgraded shares of Evommune from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, September 11th. Stifel Nicolaus set a $30.00 price objective on shares of Evommune in a research note on Wednesday, September 9th. HC Wainwright reissued a "neutral" rating on shares of Evommune in a research report on Wednesday, September 9th. UBS Group assumed coverage on Evommune in a research report on Sunday, October 11th. They issued a "neutral" rating and a $8.00 target price for the company. Finally, Royal Bank Of Canada reduced their price objective on shares of Evommune from $29.00 to $21.00 and set an "outperform" rating on the stock in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Evommune presently has a consensus rating of "Moderate Buy" and an average target price of $30.50.
Get Our Latest Research Report on Evommune
Evommune Stock Up 5.0%
The company has a fifty day simple moving average of $7.19 and a two-hundred day simple moving average of $16.85. The stock has a market capitalization of $298.63 million and a P/E ratio of -1.90.
Evommune (NYSE:EVMN - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.03). As a group, equities analysts forecast that Evommune, Inc. will post -3.37 earnings per share for the current year.
Hedge Funds Weigh In On Evommune
A number of hedge funds and other institutional investors have recently modified their holdings of EVMN. Janus Henderson Group PLC bought a new position in Evommune in the 1st quarter worth approximately $20,615,000. Stempoint Capital LP boosted its holdings in shares of Evommune by 184.1% in the first quarter. Stempoint Capital LP now owns 193,777 shares of the company's stock worth $4,385,000 after acquiring an additional 125,581 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Evommune in the first quarter valued at $10,308,000. Defilade Capital Management L.P. increased its holdings in Evommune by 215.0% during the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company's stock worth $15,601,000 after acquiring an additional 463,171 shares during the period. Finally, Eversept Partners LP purchased a new stake in shares of Evommune in the first quarter worth $1,257,000.
Evommune Company Profile
(
Get Free Report)
Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evommune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evommune wasn't on the list.
While Evommune currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.